Zurletrectinib

Overview

Zurletrectinib is a brain-penetrant, orally active TRK inhibitor ( TRKA IC 50 = 0.81 nM; TRKB IC 50 = 0.145 nM; TRKC IC 50 = 0.184 nM). Zurletrectinib exhibits stronger activity as a consequence of its augmented binding affinity for TRK kinases. Zurletrectinib exhibits higher activity against most TRK inhibitor resistance mutations (13 out of 18 mutations). Zurletrectinib can be used for the study of glioma.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Glioma | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Neuronal Signaling | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > c-Met/HGFR | Products > Signaling Pathways > Trk Receptor

Product Information

• Catalog No.: HY-148811
• CAS No.: 2403703-30-8
• Molecular Formula: C19H19F2N7O2
• Molecular Weight: 415.40
• Purity: 99.32%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 1 mg/mL (2.41 mM); Clear solution
• Availability: In-stock

Source

Original product source